政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/81473
English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  全文筆數/總筆數 : 113100/144073 (79%)
造訪人次 : 50562547      線上人數 : 690
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://nccur.lib.nccu.edu.tw/handle/140.119/81473


    題名: 生技產業新藥廠商獲利模式之探討-以某生技公司為例
    作者: 單鴻斌
    Shann, Horng Bin
    貢獻者: 季延平
    單鴻斌
    Shann, Horng Bin
    關鍵詞: 生技產業
    授權金
    新藥
    SWOT
    日期: 2015
    上傳時間: 2016-03-01 10:29:51 (UTC+8)
    摘要: 本論文的研究主題乃是針對生技產業中新藥廠商的獲利模式進行實務研究分析。由於生技產業的特性為研發時間長,且投入研發資金龐大,加上新藥產品線過少,以及營運獲利模式過於單調,如僅以自有專利技術所開發出來的新藥標的對外授權,並取得授權金的獲利模式做為主要獲利來源,如此將大幅提高公司整體的營運風險,也無法有效提升獲利績效。因此本論文研究為如何在原有的獲利模式基礎之上,再增加其他有利於加快授權並收取權利金收入,或者找出多樣化的管道來增加公司的獲利,強化本身的競爭優勢。

    本研究分析將針對實務案例公司所處產業現況與特性、及其整體營運狀況、潛在風險及獲利方式做探討。配合外部資料與訪談資料加以歸納整理,並利用SWOT分析各種可能的營運獲利模式,來發掘適合該公司的可行方案。藉由分析結果,本研究提出了三項強化的獲利模式,第一為共同研究開發模式,與國際大藥廠合作,可快速提升營運績效。第二為委託研究開發模式,可帶來更多的獲利機會。第三為向外取得新藥標的再轉授權模式,如此可縮短開發時程,以利增加未來提前再轉授權,並加速收益實現。

    本研究期望能提供給生技產業中的新藥公司做為訂定公司中長期策略目標與獲利模式方針的參考。
    The featured company for this research is Case Study Company, which specializes in the research and development of new biotech medications. Case Study Company possesses its own technological platform for the development of new monoclonal antibody (mAb) medicines, and said platform embodies the highest level of fully human mAb technologies available in the field. Due to the company’s characteristics of long R&D periods and substantial investments in research, coupled with the fact that the company has few product lines for new medications and its simple model of profit generation, Case Study Company would stand to face significant operational risks and an inability to effectively improve its performance and earnings. This will continue if it only relies on the licensing out of new drugs that it has developed with its exclusive technologies and banking on the royalties as its primary source of profit. And as such, this research shall attempt to explore other solutions that would accelerate the pace of licensing and the generation of royalties based on the company’s existing business model or to seek other means for the company to boost its earnings more rapidly and effectively. The goal of this research is to enhance the company’s business model and expand the company’s sources of profit so as to achieve profit channel diversification without being confined to specific type or format of profit generation.

    From the analysis of the primary data (from the interviews) and secondary data, together with the findings, this research proposed three solutions that would help the company to strengthen its business model. First, adopt a joint-development model. Currently, major international pharmaceutical companies are pre-emptively seeking suitable partners for collaboration in the new drug market and with opportunities for advance cooperation; the company will be able to rapidly improve its operational performance. Second, adopt a commissioned-R&D model. A model whereby the company commissions another organization to handle relevant design and development will be able to create more opportunities for profit for the company in question. Third, adopt a re-licensing model by acquiring new target drugs externally and relicensing said drugs to clients. Such a model would help the company to shorten its development lead-time and thereby improve the odds that it will be able to re-license the new drugs at an earlier time. This would accelerate the collection of royalties and profit generation for the company.
    參考文獻: 1. 周旭華譯,競爭策略 (Michael E. Porter),台北天下文化,2010年
    2. 蔡馥陞、張雍昇譯,策略管理與競爭優勢,台灣培生教育出版股份有限公司,2013年
    3. 羅敏菁,生技投資聖經,2012年
    4. 李隆生譯,生技時代的新管理,聯經出版社,2009年
    5. 朱兆文,生技製藥廠商聯盟及授權標竿案例與價值分析,財團法人生物技術開發中心,2011年
    6. 吳生皓,價值鏈分析-解剖經營活動,經理人月刊52期,2009年
    7. 楊晴輝,SWOT分析參考範例,高高屏輔導顧問,2012年
    8. 基亞生技年現金增資公開說明書,2013年
    9. 醣聯生醫現金增資公開說明書,2012年
    10. 智擎生技初次上櫃公開說明書,2012年
    11. 美時製藥年金增資暨第三次國內有擔保可轉換公司債公開說明書,2013年
    12. 林書進,台灣生技製藥公司海外直接投資進入模式之研究-以中國大陸市場為例,國立政大商管專業學院管理碩士學程論文,2010年
    13. 歐斐生,台灣生技產業經營環境與經營分析模式之應用探討,國立成功大學管理學院高階管理碩士在職專班碩士論文,2002年
    14. 許英昌,從分析歐美生技製藥及新技術發展探討台灣生技製藥產業發展方向,國立臺灣大學管理學院EMBA 碩士論文,2005年
    15. 周雅雲,影響我國生物科技廠商財務績效之因素,東吳大學經濟學系碩士論文,2005年
    16. Bagchi-Sen,S.Strategic considerations for innovation and commercialization in the US biotechnology sector,European Planning Studies,15(6) ,2007:pp.753-766
    17. Bower,D.J&Sulej,J.C. The India challenge:The evolution of a successful new global strategy in the pharmaceutical industry,Technology Analysis&Strategic Management,19(5),2007:pp.611-624
    18. ERNST&YOUNG,Beyond borders:Global biotechnology report,2009.
    19. 行政院台灣生技起飛鑽石行動方案,http://www.ey.gov.tw/ct.asp
    20. 台灣生技業搭上抗癌新藥列車專題報導,今周刊915期http://www.businesstoday.com.tw/article-content-80393-108911
    21. 論產業價值鏈,經濟學階梯教室經濟論文,http://www.gimy.com/gimywz/paper/paper_econ/
    22. 免疫療法明星創美生技IPO最大金額報導,萬寶周刊1105期,http://weekly.marbo.com.tw/
    描述: 碩士
    國立政治大學
    經營管理碩士學程(EMBA)
    100932411
    資料來源: http://thesis.lib.nccu.edu.tw/record/#G0100932411
    資料類型: thesis
    顯示於類別:[經營管理碩士學程EMBA] 學位論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    241101.pdf1126KbAdobe PDF2123檢視/開啟


    在政大典藏中所有的資料項目都受到原著作權保護.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,惟仍請適度,合理使用本網站之內容,以尊重著作權人之權益。商業上之利用,則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作,已盡力防止侵害著作權人之權益,如仍發現本網站之數位內容有侵害著作權人權益情事者,請權利人通知本網站維護人員(nccur@nccu.edu.tw),維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋